Biomarker Strategies SnapPath 1000
BioMarker Strategies has developed a unique, first of its kind instrument to capture and preserve live cells “ex-vivo”. The SnapPath® biomarker testing system is an automated live tumor cell processing platform that enables next-generation predictive tests—known as PathMap™ profiles —to guide targeted drug therapy selection for individual cancer patients. It is also one of the first of its kind to have all of the fluidics integrated into the disposable.